Novartis’s MS Pill Loses Market Share

Novartis’s MS Pill Loses Market Share

Novartis AG via Bloomberg

Gilenya’s share of the U.S. market for so-called immunomodulatory drugs against MS fell to 6.1 percent from 6.2 percent in December, according to data from Wolters Kluwer NV, a market research company.